. Materials and methods are available as supporting material on Science Online. 24 . The mean number of pretraining days in the test environment was 17 (square-circle), 14 (two rooms), and 4 (black-white). 25. The rate threshold was 0.27 Hz. Similar results were obtained with rate thresholds of 0.10 Hz and 0.50 Hz (tables S1 and S2) (23 29 . If the external spatial input is strong enough, it is theoretically possible for large changes to occur in the firing rates of some cells, whereas intrinsic attractor dynamics of the network maintain the relative relations between the place fields of the ensemble (35).
30. S. A. Hollup, S. Molden, J. G. Donnett, M.-B. Moser, E. I. Moser, Eur. J. Neurosci. 13, 1197 (2001) . 31. In these studies, which all focused on CA1, much of the residual activity in the less active condition appeared inside the cell's place field in the more active condition [e.g., figure 8 in (30), figures 3 to 5 in (14) , figures 2 to 6 in (15), figure 6 in (16) , figures 6B and 9 in (12) , and figure 4 in (13) 
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Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen. Here, we describe a full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc). Replication of HCVcc was robust, producing nearly 10 5 infectious units per milliliter within 48 hours. Virus particles were filterable and neutralized with a monoclonal antibody against the viral glycoprotein E2. Viral entry was dependent on cellular expression of a putative HCV receptor, CD81. HCVcc replication was inhibited by interferon-a and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals.
HCV is a major cause of chronic liver disease, with over 170 million persistently infected individuals worldwide (1). HCV-associated liver disease frequently progresses to cirrhosis, which can lead to liver failure and hepatocellular carcinoma. Current drug therapies are often poorly tolerated and effective in only a fraction of patients; there is no vaccine for HCV. A major obstacle to understanding the virus life cycle and to developing improved therapeutics is the inability to efficiently grow HCV in cell culture. HCV is an enveloped, positive-sense RNA virus of the family Flaviviridae. Naturally occurring variants of HCV are classified into six major genotypes. The 9.6-kb genome encodes one large polyprotein that is processed by viral and cellular proteinases to produce the virion structural proteins (core and glycoproteins E1 and E2) as well as nonstructural (NS) proteins (p7 through NS5B) (Fig. 1A) . Subgenomic RNA replicons have been adapted for efficient RNA replication in the human hepatoma line Huh-7 and other cultured cells (2-5). However, full-length genomes containing cell culture-adaptive mutations do not produce infectious virus particles in culture and are severely attenuated in vivo (6) (7) (8) . This led us to hypothesize that mutations that enhance RNA replication may have deleterious effects on virion production. To test this idea, we used a genotype 2a subgenomic replicon, SGR-JFH1, that efficiently replicates in cell culture without adaptive mutations (4). Full-length chimeric genomes were constructed with the use of the core-NS2 gene regions from the infectious J6 (genotype 2a) and H77 (genotype 1a) virus strains (Fig. 1A) . Both full-length chimeras and the subgenomic RNA were competent for RNA replication, as seen by the accumulation of NS5A protein and viral RNA 48 hours after RNA transfection into the Huh-7.5 cell line (Fig. 1B) . As expected, mutation of the NS5B RNA polymerase active site EGlyAspAsp to GlyAsnAsp (GND)d estroyed the ability of FL-J6/JFH to replicate (Fig. 1B) . Within transfected cells, both fulllength genomes expressed core, E2, and NS5A (Fig. 1C) . As expected, SGR-JFH1 expressed NS5A but not core or E2. While ,30% of cells were productively transfected with FL-J6/JFH, FL-H77/JFH, or SGR-JFH1 RNA (Fig. 1B) , 995% of FL-J6/JFH-transfected cells were positive for NS5A by 96 hours ( fig.  S1 ). This suggested that FL-J6/JFH spread within the transfected cell cultures.
To test whether infectivity could be transferred to naBve cells, we clarified conditioned media from these cultures by centrifugation (9) , filtered the supernatants (0.2 mm), and incubated them with naBve Huh-7.5 cells. NS5A expression could be transferred by the FL-J6/JFH-transfected culture media but not by media from cells transfected with FL-H77/JFH or SGR-JFH1 (Fig. 1B) . Interestingly, the amount of FL-J6/JFH RNA released into the transfected cell culture media exceeded that of the other RNAs by a factor of 9200, and only FL-J6/JFH produced an extracellular form of core (Fig. 1C, lower  panel) . Given that the infectivity of the genotype 2a chimera is filterable and is associated with the release of HCV RNA and core protein, we refer to this cell cultureproduced virus as HCVcc. The ability of the genotype 1a/2a chimera to replicate but not spread suggests that interactions between the structural and nonstructural gene products may be important for HCVcc formation, as has been observed for other members of this virus family (10, 11) .
Limiting dilution assays for NS5A expression in electroporated cells showed that 30.3 T 9.5% (n 0 6) of cells were productively transfected with FL-J6/JFH, and of these, 55% produced infectivity that was detectable upon transfer to naBve cells. Thus, FL-J6/JFH RNA transcripts were highly infectious and formation of HCVcc did not depend on the emergence of rare variants. Limiting dilution assays were also used to quantitate the amount of HCVcc infectivity between samples as median tissue culture infectious units per milliliter (TCID 50 /ml). The TCID 50 is the dilution that infects 50% of replicate cell cultures (9) . After an eclipse phase (Q9 hours), FL-J6/JFH infectivity could be detected in the media by 18 hours posttransfection, and it continued to accumulate until 48 hours (Fig.  1D) . Interestingly, FL-J6/JFH (H2476L), which contained a weakly adaptive mutation in NS5B (4), showed slightly delayed growth kinetics but also peaked to similar levels by 48 hours. Viruses could be serially passaged, infecting 50 to 90% of cells within 5 days after two rounds of passage at a low multiplicity of infection (MOI) of 0.1 to 1.0 (Fig.  1E) . The expression and subcellular localization of core, E2, and NS5A within FL-J6/JFHinfected cells was consistent with what was previously seen in full-length and subgenomic replicon-bearing cells Esupporting online material (SOM) text^. Taken together, these measurements show that HCVcc replication is robust and occurs with kinetics similar to those of other Flaviviridae.
A classic method in virus identification is to neutralize the suspected virus with specific antisera. As shown in Fig. 2A , an E2-specific human monoclonal antibody neutralized HCVcc infectivity in a dose-dependent manner, whereas an isotype-matched control antibody had no effect on HCVcc titer. These data affirm the viral nature of HCVcc infectivity and show that E2 is essential for virus entry.
HCV E2 has been shown to bind to the cellular surface protein CD81 (12) , which is an essential coreceptor for the entry of HCV glycoprotein-pseudotyped retroviruses (13) (14) (15) . We found that HCVcc infectivity could be blocked with a soluble recombinant form of the CD81 large extracellular loop (Fig. 2B) . To further examine the role of CD81 in virus entry we used HepG2 cells, which lack CD81 expression but are capable of supporting HCV RNA replication (3). As seen in Fig. 2C , normal HepG2 cells were not infected by FL-J6/JFH, whereas CD81-expressing HepG2 cells were infected under the same conditions, albeit with reduced efficiency (,850 times less than Huh-7.5 cells). These data confirm that interactions between E2 and CD81 are important for HCV entry.
The physical nature of HCV particles has been difficult to study in the absence of an infectious culture system. In density gradients, clinical isolates of HCV exhibit a broad distribution and unusually low buoyant densities Ereviewed in (16)^. These properties have been partly explained by the interaction of HCV with serum components such as immunoglobulins and b-lipoproteins. We examined the profiles of RNA and infectivity associated with HCVcc particles by equilibrium centrifugation in 10 to 40% iodixanol, an iso-osmotic gradient material. A series of controls confirmed that this method accurately measured the buoyant density of HCVcc (SOM text). HCV RNA was broadly distributed through the top of the gradient, with a peak in fractions 16 and 17 (1.13 to 1.14 g/ml), and was not found beyond fraction 20 (1.18 g/ml) (Fig.  3A) . HCVcc infectivity was also broadly distributed among fractions 1 to 15 (1.01 to 1.12 g/ml), and infectivity was not seen beyond fraction 18 (1.17 g/ml). Surprisingly, fractions 16 and 17, which contained the highest levels of HCV RNA, had little infectivity associated with them. The specific infectivity of a virus preparation relates the amount of infectivity to the total number of virus particles or genomes in the preparation. Interestingly, a plot of HCVcc-specific infectivity versus buoyant density indicates that the most infectious material is at 1.09 to 1.10 g/ml (Fig. 3B) , which is similar to the peak of infectivity (1.09 to 1.11 g/ml) previously seen in chimpanzees (17) . In contrast, RNAcontaining material with a buoyant density of 1.14 g/ml (fraction 17) had a low specific infectivity, with ,300,000 RNA molecules per infectious unit. Many groups have reported an HCV RNA peak near this density (18) (19) (20) , although infectivity could not be assessed. Thus, HCVcc exhibits physical properties similar to those that have been previously described for natural isolates of HCV.
There is an urgent need for improved HCV drug therapies. The current standard treatment, pegylated interferon-a (IFNa) and ribavirin, leads to a sustained response in only ,50% of genotype 1-infected patients. We examined the ability of HCVcc replication to be inhibited by IFNa and other antiviral compounds. Doseresponse experiments showed that IFNa inhibited HCVcc RNA accumulation in infected cells with a median effective concentration (EC 50 ) of 1 international unit (IU)/ml (Fig.  4A) . We also tested three HCV-specific inhibitors of the NS3 serine protease for their effects on HCVcc infection. As seen in Fig.  4 , B to D, BILN 2061 (21), SCH6 (22) , and PI-1 (23) all inhibited HCVcc RNA accumulation in the submicromolar range. In addition, a nucleoside analog inhibitor of the NS5B RNA polymerase, 2 ¶C-methyladenosine (24) , was found to inhibit HCVcc replication in the low nanomolar range (Fig. 4E) . Thus, HCVcc infection can be inhibited by IFNa and several HCV-specific antiviral compounds. The specificity of these latter compounds further shows that HCVcc infection leads to authentic replication in target cells and demonstrates that this infectious system may be useful for testing current and future antiviral compounds.
We describe a full-length genotype 2a HCV genome that replicates and produces virus particles that are infectious in cell culture.
This system lays a foundation for future in vitro studies to examine new aspects of the virus life cycle and to develop new drugs for combating HCV.
Note added in proof: Full-length JFH-1 has also been recently reported to produce infectious virus in cell culture (25) (26) (27) , as has a genotype 1b Com1/JFH-1 chimera (28), albeit with lower efficiency and slower growth kinetics than the system reported here.
